Grail Stock Earnings Reports

GRAIL reported strong commercial momentum in Q1 2026, selling over 56,000 Galleri tests (up 50% YoY) and generating $39.8M in screening revenue (up 37% YoY). Total revenue was $40.8M; net loss narrowed to $93.2M and adjusted EBITDA improved to negative $79.9M. Cash totaled $823.1M. Key commercial progress includes expanded health-system partnerships (Dana-Farber, Cleveland Clinic, Duke, OHSU, Rush), growing employer and digital-health relationships (Function Health, Hims & Hers, WHOOP), and integrations with Quest, Athena and a newly announced Epic Aura integration to enable ordering and results within EHR workflows. GRAIL’s FDA PMA for Galleri was submitted and accepted for review, supported by ~25,000 PATHFINDER 2 participants and NHS-Galleri prevalence data; the company is hopeful the test aligns with recent rapid CMS-FDA pathways but awaits regulatory detail. Clinically, GRAIL highlighted NHS-Galleri findings showing increased detection of Stage I/II "deadly cancers," a fourfold higher cancer detection rate vs. standard screening, and meaningful reductions in Stage IV diagnoses and emergency presentations—outcomes it will present in full at ASCO 2026 alongside PATHFINDER 2 data. Management is expanding the salesforce (from ~90 to ~120 territories) with most hires to be onboarded by midyear; they are reiterating 2026 revenue guidance (22%–32% growth) while noting catalysts (ASCO data, salesforce expansion, Epic integration, and potential FDA action) that could affect momentum later in the year. Pricing (ASPs) has moderating downward pressure by design to drive scale, with modest further declines expected primarily driven by channel mix and targeted discounting.